BioMark Diagnostics (TSE:BUX) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioMark Diagnostics Inc. has made strides in cancer detection by publishing a study on identifying metabolomic biomarkers for pulmonary neuroendocrine neoplasms (NENs), which could enhance early diagnosis and patient management. Their liquid biopsy technology shows potential for non-invasive, cost-effective, and accurate detection of NENs and other cancers, funded by a MEDTEQ+ research grant.
For further insights into TSE:BUX stock, check out TipRanks’ Stock Analysis page.